A total of 1,680 adults and 41 adolescents were randomly assigned to brensocatib or placebo. The researchers found that the annualized rate of pulmonary exacerbations was 1.02, 1.04, and 1.29 in ...

Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1, may lower the rate of pulmonary exacerbations in patients with bronchiectasis. New research findings are summarized in a short ...

He was also affected by his “previous episode of acute respiratory failure in bilateral multimicrobial pneumonia, multiple bronchiectasis, arterial hypertension and type II diabetes ...

He had also suffered from arterial hypertension, multiple bronchiectasis and Type 2 diabetes — something that was not previously known. It was signed by the director of health of the Vatican ...

Finally, itepekimab is being explored in a phase 2 study (clinical study identifier: NCT06280391) in bronchiectasis, with the readout anticipated in 2026. About amlitelimabAmlitelimab is a fully ...

New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma Lunsekimig now targeting chronic rhinosinusitis and COPD in addition to asthma Itepekimab expanding into chronic ...

In the Phase III EXPECTS trial, patients experiencing mostly mild posterior circulation ischemic stroke who were ineligible for thrombectomy showed significantly better functional recovery at 90 days ...

Insmed Incorporated develops therapies for serious and rare diseases, with treatments like ARIKAYCE for lung infections and brensocatib for bronchiectasis in clinical trials. The Bridgewater ...

Millions of people living with bronchiectasis could potentially benefit from a breakthrough investigational therapy – brensocatib – following the announcement of new trial findings.

The BnF’s Museum covers the full extent of the Library’s collections, from Antiquity to the present day. Almost 900 outstanding items are on exhibition and regularly renewed, along an itinerary across ...